Migraine Medication Effects on Urinary Symptoms

Inclusion Criteria: * Female Patients \> 18 years * Refractory migraine, planned treatment with either: * CGRP inhibitors, including: * CGRP small molecule receptor antagonists ("gepants"): Ubrogepant, Rimegepant, Atogepant. * CGRP monoclonal antibodies: Eptinezumab, Fremanezumab, Galcanezumab. * CGRP receptor monoclonal antibodies: Erenumab. * BoNTA extracranial muscle injections * Any of the following symptoms during the last month: * Urinating too often (frequency). * Having a sudden urge to urinate that's difficult to hold back (urgency). * Having a sudden urge to urinate and urine leaking before you make it to the toilet (urge incontinence). Exclusion Criteria: * Age \< 18 years * CGRP treatment within the last 12 months or BoNTA (head / bladder) last 6 months. * Patient (or medical decision-maker) unable to provide informed consent or unable to answer questionnaire. * Unable to urinate, eg: post cystectomy, indwelling catheter, on intermittent self catheterization, ESRD w/ anuria. * Prior bladder BoNTA in last 12 months.